ELI LILLY AND COMPANY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 225.3 CHF | -1.50% |
|
-58.28% | -58.28% |
| 12:08pm | Jefferies Adjusts Price Target on Eli Lilly to $957 From $925 | MT |
| 08:15am | US FDA Staff Flags Potential Limited Benefit of Eli Lilly's Alzheimer's Disease Drug | MT |
| Sales 2024 * | 4.3TCr 3.82TCr 3,58300Cr | Sales 2025 * | 5.26TCr 4.68TCr 4,38800Cr | Capitalization | 75TCr 67TCr 62,85600Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 1.19TCr 1.06TCr 99TCr | Net income 2025 * | 1.66TCr 1.47TCr 1,38000Cr | EV / Sales 2024 * | 18 x |
| Net Debt 2024 * | 1.81TCr 1.61TCr 1,50700Cr | Net Debt 2025 * | 1.5TCr 1.33TCr 1,25000Cr | EV / Sales 2025 * | 14.6 x |
| P/E ratio 2024 * |
62.6
x | P/E ratio 2025 * |
45.1
x | Employees | 43,000 |
| Yield 2024 * |
0.62% | Yield 2025 * |
0.72% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -1.50% | ||
| 1 week | -58.28% | ||
| Current month | -58.28% | ||
| 1 month | -58.28% | ||
| 3 months | -58.28% | ||
| 6 months | -58.28% | ||
| Current year | -58.28% |
1 year
225.31
540.00
3 years
197.73540.00
5 years
108.90540.00
10 years
53.92540.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/23/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/24/06 | - | +-NaN% | 281 |
| 05/24/05 | - | +-NaN% | 557 |
| 04/24/04 | - | +-NaN% | 37,175 |
| 03/24/03 | - | +-NaN% | 454 |
| 31/24/31 | - | +-NaN% | 677 |
Delayed Quote London S.E., December 10, 2021 at 08:07 pm IST
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
837.3
USD
Average target price
853.8
USD
Spread / Average Target
+1.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.09% | 63TCr | |
| -6.58% | 35TCr | |
| +19.72% | 33TCr | |
| +8.78% | 30TCr | |
| +11.98% | 22TCr | |
| -1.10% | 22TCr | |
| +0.03% | 16TCr | |
| +6.13% | 16TCr | |
| +0.22% | 12TCr |
- Stock Market
- Equities
- LLY Stock
- LEL Stock
